Therefore, this study aimed to investigate the efficacy and safety of tucidinostat plus exemestane as a neoadjuvant strategy in early-stage breast cancer with hormone receptor-positive and HER2-negative (ChiCTR2100046678). This evidence concerns the gene NR4A1 and breast carcinoma.